– A survey of 1,165 biopharma operators and healthcare policymakers across 20 countries measured the industry’s ability to respond to global needs in five areas: Supply chain sustainability, talent pool, R&D ecosystem, manufacturing flexibility, and government policy and regulation.
– There is a strong correlation between higher performing countries and higher per capita incomes; United States manages the index as a whole but Switzerland and China you have the most stable supply chains
– Such an initial study to address a wide range of topics and respondents
AMERSHAM, United Kingdom, March 9, 2021 / PRNewswire / – Cytiva ‘s global life sciences director, along with the Financial Times’ research arm, has compiled a global index, ranking the biopharma industry’ s ability to address five key challenges; in supply chain, talent, research and development, manufacturing, and government policy and regulation.
Respondents answered questions on a scale of 1 to 10 in each of the five domains. The average of all responses resulted in a rating of each country’s biopharma capabilities as well as global industry strength. With an overall index score of 6.6 out of 10, the industry looks vulnerable – and has the opportunity to improve across a number of critical areas. In the full table of contents, United States runs first, with a score of 7.12. Switzerland and the UK closely following.
Russia, China and India leads in middle-income and middle-income countries1, despite having large numbers and lower GNI per capita than some of the other countries in this group. However, the index also highlights a clear distinction between high-income vs. middle-income and low-middle-income economies. The high-income and middle-income economies tend to score lower on the index: this indicates that biopharma industries are less robust. which poses a significant threat to global access to essential medicines.
Emmanuel Ligner, President and CEO, Cytiva, says: “As a partner to global biopharma companies, we wanted to offer this overview of where the industry is performing well, and where Some pain points.The data is built by listening to customers and key players, and giving us insight into major concerns.With this data, we have even more productive conversations and be more prepared working with customers and stakeholders to address industry-wide challenges. ”
Kiran Mazumdar-Shaw, founder and chairman of Biocon, says: “Biopharma has a big role to play in the future of medicine, and many of the medicines that we are developing now will change games. But it should not be The development of blockchain drugs is about to make a billion dollars – it should be about serving a billion patients. That’s when we have global equity in healthcare. “
The index was compiled from 1,165 survey respondents across 20 countries (95% pharma and biopharma officers and 5% health care policy makers), as well as in-depth interviews with eight experts from biopharma and health care policy making.
For the full report and more facts, visit this page.
About Cytiva
Cytiva is a global life sciences leader with more than 7,000 participants across 40 countries dedicated to the advancement and acceleration of therapeutic medicine. As a trusted partner for customers that go in scale and breadth, Cytiva brings speed, efficiency and capability to research and manufacturing workflows, enabling the development, manufacture and delivery of formulations. -changeable for patients.
1 Using World Bank country classification, based on each person’s gross national income
Cytiva STORAGE
